Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ayr Wellness Inc. stock logo
AYRWF
Ayr Wellness
$0.04
+7.7%
$0.13
$0.00
$2.60
$4.39M1.71592,853 shs365,669 shs
GSTC
GlobeStar Therapeutics
$0.00
$0.00
$0.00
$120K2.511.08 million shsN/A
NephroGenex, Inc stock logo
NRXGQ
NephroGenex
$0.00
$0.00
$0.21
$36KN/A26,223 shs2,000 shs
OREXQ
Orexigen Therapeutics
$0.01
+35.9%
$0.01
$0.00
$0.16
$100K4.9880,439 shs60,300 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ayr Wellness Inc. stock logo
AYRWF
Ayr Wellness
+0.29%-19.86%-78.73%-85.45%-98.29%
GSTC
GlobeStar Therapeutics
0.00%0.00%0.00%0.00%-80.00%
NephroGenex, Inc stock logo
NRXGQ
NephroGenex
0.00%0.00%0.00%0.00%0.00%
OREXQ
Orexigen Therapeutics
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Ayr Wellness Inc. stock logo
AYRWF
Ayr Wellness
2.8056 of 5 stars
3.34.00.00.02.80.01.3
GSTC
GlobeStar Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
NephroGenex, Inc stock logo
NRXGQ
NephroGenex
N/AN/AN/AN/AN/AN/AN/AN/A
OREXQ
Orexigen Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ayr Wellness Inc. stock logo
AYRWF
Ayr Wellness
2.50
Moderate Buy$3.007,836.51% Upside
GSTC
GlobeStar Therapeutics
0.00
N/AN/AN/A
NephroGenex, Inc stock logo
NRXGQ
NephroGenex
0.00
N/AN/AN/A
OREXQ
Orexigen Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ayr Wellness Inc. stock logo
AYRWF
Ayr Wellness
$463.63M0.01N/AN/A$3.14 per share0.01
GSTC
GlobeStar Therapeutics
N/AN/AN/AN/AN/AN/A
NephroGenex, Inc stock logo
NRXGQ
NephroGenex
N/AN/AN/AN/AN/AN/A
OREXQ
Orexigen Therapeutics
$33.71M0.00N/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ayr Wellness Inc. stock logo
AYRWF
Ayr Wellness
-$359.31M-$3.26N/AN/AN/A-77.50%-31.73%-11.73%N/A
GSTC
GlobeStar Therapeutics
-$1.95MN/A0.00N/AN/AN/AN/AN/AN/A
NephroGenex, Inc stock logo
NRXGQ
NephroGenex
N/AN/A0.00N/AN/AN/AN/AN/AN/A
OREXQ
Orexigen Therapeutics
-$24.52MN/A0.00N/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Ayr Wellness Inc. stock logo
AYRWF
Ayr Wellness
N/AN/AN/AN/AN/A
GSTC
GlobeStar Therapeutics
N/AN/AN/AN/AN/A
NephroGenex, Inc stock logo
NRXGQ
NephroGenex
N/AN/AN/AN/AN/A
OREXQ
Orexigen Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ayr Wellness Inc. stock logo
AYRWF
Ayr Wellness
1.10
1.60
0.57
GSTC
GlobeStar Therapeutics
N/AN/AN/A
NephroGenex, Inc stock logo
NRXGQ
NephroGenex
N/AN/AN/A
OREXQ
Orexigen Therapeutics
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Ayr Wellness Inc. stock logo
AYRWF
Ayr Wellness
0.91%
GSTC
GlobeStar Therapeutics
0.01%
NephroGenex, Inc stock logo
NRXGQ
NephroGenex
N/A
OREXQ
Orexigen Therapeutics
N/A

Insider Ownership

CompanyInsider Ownership
Ayr Wellness Inc. stock logo
AYRWF
Ayr Wellness
8.10%
GSTC
GlobeStar Therapeutics
2.50%
NephroGenex, Inc stock logo
NRXGQ
NephroGenex
N/A
OREXQ
Orexigen Therapeutics
13.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ayr Wellness Inc. stock logo
AYRWF
Ayr Wellness
2,440116.19 million106.77 millionNot Optionable
GSTC
GlobeStar Therapeutics
11.24 billion1.21 billionNot Optionable
NephroGenex, Inc stock logo
NRXGQ
NephroGenex
1,70012.95 millionN/ANot Optionable
OREXQ
Orexigen Therapeutics
13218.89 millionN/ANot Optionable

Recent News About These Companies

Axsome Therapeutics Inc (AXSM)
Heron Therapeutics Inc HRTX
Regulation of Appetite to Treat Obesity

New MarketBeat Followers Over Time

Media Sentiment Over Time

Ayr Wellness stock logo

Ayr Wellness OTCMKTS:AYRWF

$0.04 +0.00 (+7.69%)
As of 03:52 PM Eastern

Ayr Wellness Inc. operates as a vertically-integrated multi-state cannabis operator that cultivates, manufactures, and retails cannabis products and branded cannabis packaged goods. It owns and operates a chain of cannabis retail stores under AYR, Liberty Health Sciences, and The Dispensary brand names. The company was formerly known as Ayr Strategies Inc. and changed its name to Ayr Wellness Inc. in February 2021. Ayr Wellness Inc. was incorporated in 2017 and is headquartered in Miami, Florida.

GlobeStar Therapeutics OTCMKTS:GSTC

GlobeStar Therapeutics Corporation, a clinical stage pharmaceutical company, focuses on developing a patented formulation of drugs for the treatment of multiple sclerosis and other neurodegenerative diseases. It offers Amethyst, a compound intended to treat neurodegeneration. The company was formerly known as AngioSoma, Inc. and changed its name to GlobeStar Therapeutics Corporation in July 2021. GlobeStar Therapeutics Corporation is based in Richland, Washington.

NephroGenex stock logo

NephroGenex OTCMKTS:NRXGQ

NephroGenex, Inc. is a pharmaceutical company. The Company is focused on the development of therapeutics to treat kidney disease. The Company has paused the clinical program of its product candidate, oral Pyridorin, for the treatment of diabetic nephropathy. The Company was primarily focused on the Phase III Pyridorin program, and other planned clinical and nonclinical studies and other work needed to submit Pyridorin for acute kidney injury (AKI), as well as the treatment of diabetic nephropathy in patients with Type II diabetes for regulatory approval in the United States and Europe. The Company has not generated any revenues.

Orexigen Therapeutics OTCMKTS:OREXQ

$0.0053 +0.00 (+35.90%)
As of 05/31/2019

Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products primarily in the United States, Europe, and South Korea. It offers Contrave for the treatment of obesity. The company also offers Contrave under the Mysimba brand name. Orexigen Therapeutics, Inc. was founded in 2002 and is headquartered in La Jolla, California. On March 12, 2018, Orexigen Therapeutics, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.